Beyond Humira: How AbbVie Plans To Hold Its Immunology Leadership Reign

AbbVie detailed plans for a pair of late-stage immunology candidates – an anti-IL-23 drug and a JAK1 inhibitor – that it says point to a bright future in immunology after Humira's patent expires during an R&D day.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America